J&J: publication of data for Covid-19 candidate vaccine

(CercleFinance.com) - Johnson & Johnson has said that the New England Journal of Medicine has published interim Phase 1/2a data showing that the Covid-19 candidate vaccine, developed by the Janssen Pharmaceutical Companies, provided an immune response of at least 71 days in study participants aged 18 to 55 years.


Data on the durability of immune responses in trial participants over 65 years of age will be available at the end of January and a longer-term follow-up of up to one year is planned, the laboratory says.

The company plans to present its Phase 3 data at the end of January.

Copyright (c) 2021 CercleFinance.com. All rights reserved.